Patients regained 5.1% of weight after the one-time endoscopic procedure versus 8.2% with sham, keeping about 80% of their GLP-1 weight loss, per trial data.
Recap by typeshit. Full story at HCPLive.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
A short explainer on how the brand Wegovy relates to its active ingredient, semaglutide. Only the question itself is available here.
Healio
The doctor screens for thyroid cancer history, pancreatitis and gallbladder disease before starting incretin drugs, and checks in within four weeks of each dose step.
Loading…